Basic Science Review
What's the next best cytokine target in IBD?
Article first published online: 16 APR 2012
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 11, pages 2180–2189, November 2012
How to Cite
MacDonald, T. T., Biancheri, P., Sarra, M. and Monteleone, G. (2012), What's the next best cytokine target in IBD?. Inflamm Bowel Dis, 18: 2180–2189. doi: 10.1002/ibd.22967
- Issue published online: 15 OCT 2012
- Article first published online: 16 APR 2012
- Manuscript Accepted: 5 MAR 2012
- Manuscript Received: 20 FEB 2012
- T cell;
In the gut of patients with inflammatory bowel disease (IBD), immune and nonimmune cells produce large amounts of cytokines that drive the inflammatory process leading to the tissue damage. Cytokine blockers, such as anti-tumor necrosis factor alpha (TNF-α), have been used with some success in IBD. However, not all patients respond, and the therapeutic effects wane with time, demonstrating the need for more effective and long-lasting antiinflammatory strategies. A key question is whether neutralizing other proinflammatory cytokines such as interleukin (IL)-12, IL-21, IL-27, or IL-33 will lead to a better clinical response than with anti-TNF-α antibodies. Equally, we now know that IBD-related inflammation is marked by defective production/activity of antiinflammatory cytokines, and there are strategies to correct these defects. An alternative approach is to try to target individual therapies to individual patients, to improve clinical efficacy in subsets of patients, but this has proven difficult. Here we try to evaluate the potential of each of these choices. (Inflamm Bowel Dis 2012;)